Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …

BTK is a kinase that functions downstream of multiple receptors in various hematologic cells.
This review focuses on BTK-dependent pathways that are likely to be involved in …

Purpose Survival and progression of mature B-cell malignancies depend on signals from the
B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this …

Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation
and maintenance of B-cell malignancies and autoimmune diseases. The Bruton tyrosine …

Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell
and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical …

NF-κB is usually activated by signal-induced, ubiquitin-mediated degradation of its inhibitor,
IκB. This process is initiated by phosphorylation of IκB by the IκB kinase (IKK) complex …

Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular
and molecular mechanisms by which Btk mediates inflammation are poorly understood …

Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the
treatment of B cell malignancies. However, further refinement is needed to this class of …

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating
subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for …

Introduction The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective
inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune …